Drug Trial Radar · NCT07898072
Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Mar 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Amneal Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Avant Sante Research Center S.A. de C.V.
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase 3 clinical trial is to evaluate the safety, efficacy, and usability of a weekly subcutaneous testosterone cypionate auto-injector in adult males with hypogonadism. The main questions it aims to answer are: * Does weekly testosterone cypionate administered using an auto-injector maintain testosterone levels within the normal range in adult males with hypogonadism? * What side effects and safety outcomes occur during treatment with testosterone cypionate auto-injector? * Is the auto-injector easy for participants to use and self-administer? All participants will receive testosterone cypionate administered subcutaneously once weekly through an auto-injector. Treatment will begin at a 75 mg weekly dose, with dose adjustments to 50 mg or 100 mg based on testosterone levels measured during the study. Participants will: * Receive weekly testosterone cypionate injections using an auto-injector for up to 52 weeks. * Attend regular clinic visits for physical examinations, laboratory tests, blood pressure monitoring, and safety assessments. * Provide blood samples to measure testosterone and other hormone levels and evaluate pharmacokinetics. * Complete questionnaires related to symptoms, quality of life, and ease of use of the auto-injector. * Record self-administration and treatment compliance in a study diary. This study will enroll adult males aged 18 to 75 years with hypogonadism and low testosterone concentrations to evaluate treatment through Week 24, with continued safety follow-up through Week 52.
Conditions
- Male Hypogonadism
Interventions
Testosterone Cypionate 75 mgDrug
Testosterone cypionate injectable solution formulated in cottonseed oil, supplied in a single-use auto-injector containing 75 mg/0.5 mL. The study drug will be administered subcutaneously into the abdomen once weekly. All participants will initiate treatment at 75 mg once weekly, with dose adjustments in 25 mg increments to 50 mg or 100 mg based on serum total testosterone trough concentrations according to protocol-defined criteria. Treatment will continue through the 24-week primary evaluation period, with eligible participants permitted to continue once-weekly treatment through Week 52 for extended safety assessment.
Testosterone cypionate 50 mgDrug
Testosterone cypionate injectable solution formulated in cottonseed oil, supplied in a single-use auto-injector containing 50 mg/0.5 mL. The study drug will be administered subcutaneously into the abdomen once weekly. All participants will initiate treatment at 75 mg once weekly, with dose adjustments in 25 mg increments to 50 mg or 100 mg based on serum total testosterone trough concentrations according to protocol-defined criteria. Treatment will continue through the 24-week primary evaluation period, with eligible participants permitted to continue once-weekly treatment through Week 52 for extended safety assessment.
Testosterone cypionate 100 mgDrug
Testosterone cypionate injectable solution formulated in cottonseed oil, supplied in a single-use auto-injector containing 100 mg/0.5 mL. The study drug will be administered subcutaneously into the abdomen once weekly. All participants will initiate treatment at 75 mg once weekly, with dose adjustments in 25 mg increments to 50 mg or 100 mg based on serum total testosterone trough concentrations according to protocol-defined criteria. Treatment will continue through the 24-week primary evaluation period, with eligible participants permitted to continue once-weekly treatment through Week 52 for extended safety assessment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Average Serum Total Testosterone Concentration Within 300-1100 ng/dL at Week 12Time frame: Week 12 (over the 168-hour dosing interval following the Week 12 dose)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
University of California (UCLA) (Site ID 111)
Santa Monica, California · Not yet recruiting
Accel Research Site Alcanza Clinical Research (Site ID 103)
DeLand, Florida · Not yet recruiting
Floridian Clinical Research LLC (Site ID 101)
Miami Lakes, Florida · Recruiting
Quality Research Center (Site ID 104)
Omaha, Nebraska · Recruiting
AccuMed Research Associates (Site ID 106)
Garden City, New York · Recruiting
Integrated Medical Professionals/Advanced Urology Centers of New York (Site ID 107)
New York, New York · Not yet recruiting
Brown University (Site ID 108)
Providence, Rhode Island · Not yet recruiting
Coastal Carolina Research Center (Site ID 102)
North Charleston, South Carolina · Not yet recruiting
Biobehavioral Research Center of Austin (Austin TX) (Site ID 105)
Austin, Texas · Recruiting
Baylor College of Medicine (Site ID 109)
Houston, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.